Shinichi Niwano
Clinical Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Background Catheter ablation (CA) can improve exercise tolerance and quality of life (QOL) in patients with atrial fibrillation (AF). However, its differential effects on muscle strength between paroxysmal AF (PAF) and nonparoxysmal AF (Non‐PAF) remain unclear. Methods We evaluated 94 patients (67.8 ± 10.3 years old, 71% male) who underwent CA (PAF/Non‐PAF 46/48) without AF recurrence. Six‐minute walk distance (6MWD), leg strength, and an AF‐specific QOL questionnaire (AFQLQ) were evaluated at baseline, 3, and 6 months after CA. Results At baseline, the 6MWD and AFQLQ subset 3 score were significantly lower in patients with PAF than in those with Non‐PAF, but the parameters of muscle strength were comparable between the two groups. Both 6MWD and AFQLQ significantly improved at 6 months after CA in both groups. However, leg strength at 6 months after CA significantly improved in the Non‐PAF group (54.9 ± 16.5 to 58.4 ± 15.2, p < .05) but not in the PAF group. Conclusion Successful CA for both PAF and Non‐PAF improved QOL and exercise tolerance. Additionally, CA improved leg strength in Non‐PAF patients.
Year:
2025
Background The prognostic impact of atrial fibrillation (AF) and oral anticoagulation (OAC) therapy in patients with type B acute aortic dissection (AAD) remains unclear. Therefore, we investigated the prognostic impact of AF and OAC therapy in patients with type B AAD. Methods Consecutive patients diagnosed with AAD were included in this single‐center, retrospective study. Patients with type B AAD were selected from the study population and divided into three groups: AF(+)/OAC(+), AF(+)/OAC(−), and AF(−)/OAC(−). The primary end point was major adverse cardiovascular and cerebrovascular events (MACCE), including all‐cause death, progressive aortic events, cerebral infarction, and organ malperfusion. Results In total, 139 patients diagnosed with type B AAD were analyzed. AF was observed in 27 patients (19%). Among them, 13 patients (9%) received OAC therapy for AF. MACCE occurred in 32 patients (23%) during the observation period: all‐cause death in four patients, progressive aortic events in 24 patients, cerebral infarction events in two patients, and malperfusion events in two patients. The incidence of MACCE was higher in the AF(+)/OAC(+) group than in the AF(+)/OAC(−) group (hazard ratio[HR]: 3.875; 95% confidence interval [CI]: 1.153–17.496). In contrast, there was no significant difference in the incidence of MACCE between the AF(+)/OAC(−) and AF(−)/OAC(−) groups (HR: 1.001, 95% CI: 0.509–1.802). Conclusion Among patients with type B AAD, the use of OAC for AF was associated with a higher risk of MACCE.
Year:
2024
Collaborators (2)
Hidehira Fukaya
Junior Associate Professor
Kitasato University School of Medicine
Junya Ako
Kitasato University
Make your next move.
Prepare your application
Review drafts before you send them.